[1] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2] Wong RJ, Ahmed A, Gish RG.Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders[J]. Clin Liver Dis,2015,19(2):309-323.
[3] Bruix J Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020-1022.
[4] Liebman HA, Furie BC, Tong MJ, et al.Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J]. N Engl J Med,1984,310(22):1427-1431.
[5] Ueda N, Shiraha H, Fujikawa T, et al.Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines[J]. Mol Oncol,2008,2(3):241-249.
[6] Bertino G, Ardiri A, Malaguarnera M, et al.Hepatocellua-lar carcinoma serum markers[J]. Semin Oncol,2012,39(4):410-433.
[7] Shearer MJ, Newman P.Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis[J]. J Lipid Res,2014,55(3):345-362.
[8] Murata K, Suzuki H, Okano H, et al.Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma[J]. Int J Oncol,2009,35(5):1005-1014.
[9] Zhang Q, Bai X, Chen W, et al.Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling[J]. Carcinogenesis,2013,34(5):962-973.
[10] Suzuki H, Murata K, Gotoh T, et al.Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma[J]. J Gastroenterol,2011,46(10):1219-1229.
[11] Zhang YS, Chu JH, Cui SX, et al.Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma[J]. Cell Physiol Biochem,2014,34(3):903-915.
[12] Matsubara M, Shiraha H, Kataoka J, et al.Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2012,27(10):1602-1608.
[13] Kokudo N, Hasegawa K, Akahane M, et al.Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res,2015, 45(2):123-127.
[14] Cui SX, Shi WN, Song ZY, et al. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways[J/OL]. Oncotarget,2016-05-04[2016-05-19]. https://www.ncbi.nlm.nih.gov/pubmed/27167344.
[15] 高明军, 陈洪, 陆枫林, 等. 去γ-羧基凝血酶原、甲胎蛋白在原发性肝细胞癌中的诊断价值[J]. 实用医学杂志,2012,28(15):2516-2519.
[16] Song P, Feng X, Inagaki Y, et al.Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects[J]. Biosci Trends,2014,8(5):266-273.
[17] Li C, Zhang Z, Zhang P, et al.Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review[J]. Hepatol Res,2014,44(10):E11-E25.
[18] 中国医疗保健国际交流促进会, 北方肝癌治疗专家委员会. 北方肝癌治疗专家委员会肝细胞癌诊疗共识(草案)[J]. 肝癌电子杂志,2014,1(1):1-13.
[19] Forner A, Llovet JM, Bruix J.Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255.
[20] Izzo F, Piccirillo M, Albino V, et al.Prospective scree-ning increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients[J]. HPB (Oxford),2013,15(12):985-990.
[21] Yamashita Y, Shirabe K, Aishima S, et al.Predictors of microvascular invasion in hepatocellular carcinoma[J]. Dig Dis,2015,33(5):655-660.
[22] Yamashita Y, Tsuijita E, Takeishi K, et al.Predictors for microinvasion of small hepatocellular carcinoma ≤2 cm[J]. Ann Surg Oncol,2012,19(6):2027-2034.
[23] Shirabe K, Toshima T, Kimura K, et al.New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma[J]. Liver Int,2014,34(6):937-941.
[24] Yamamoto K, Imamura H, Matsuyama Y, et al.Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy[J]. Ann Surg Oncol,2009,16(10):2795-2804.
[25] Toyoda H, Kumada T, Tada T, et al.Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy[J]. J Hepatol,2012,57(6):1251-1257.
[26] 陈继军, 杨宏勋, 李超, 等. AFP和DCP在肝癌患者预后评价中的作用[J]. 国际外科学杂志, 2014,40(4):233-237.
[27] Okamura Y, Ashida R, Ito T, et al.The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma[J]. Surg Today,2015,45(12):1513-1520.
[28] Masuda T, Beppu T, Horino K, et al.Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma[J]. J Surg Oncol,2010,102(5):490-496.
[29] Ito T, Takada Y, Ueda M, et al.Expansion of selection criteria for patients with hepatocellular carcinoma in livi-ng donor liver transplantation[J]. Liver Transpl,2007,13(12):1637-1644.
[30] Kaido T, Ogawa K, Mori A, et al.Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma[J]. Surgery,2013,154(5):1053-1060.
[31] Tameda M, Shiraki K, Sugimoto K, et al.Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma[J]. Cancer Sci,2013,104(6):725-731.
[32] Sumi A, Akiba J, Ogasawara S, et al.Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma[J]. PLoS One,2015,10(3):e0118452.
[33] Kurokawa T, Yamazaki S, Mitsuka Y, et al.Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin[J]. Br J Cancer,2016,114(1):53-58.
[34] Toyoda H, Kumada T, Osaki Y, et al.Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report[J]. Cancer Sci,2012 ,103(5):921-925.
[35] Saito M, Yano Y, Hirano H, et al.The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma[J]. Cancer Biomark,2016,16(1):171-180.
[36] Carr BI, Wang Z, Wang M, et al.Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines[J]. Dig Dis Sci,2011,56(6):1876-1883.
[37] Inagaki Y, Qi F, Gao J, et al.Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth[J]. Biosci Trends,2011,5(2):52-56. |
